Lauren Miller
Nephrology · Hermitage, TNNPI 1245506518
Payments from drug & device makers
Across 114 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$555
- AbbVie$336
- SK Life Science, Inc.$114
- Tanabe Pharma America, Inc.$113
- Eisai Inc.$92
- AstraZeneca$86
- plus $967 from 27 others
What the payments were for
- Food & beverage$2,264100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 29 | $555 |
| AbbVie | 18 | $336 |
| SK Life Science, Inc. | 6 | $114 |
| Tanabe Pharma America, Inc. | 6 | $113 |
| Eisai Inc. | 5 | $92 |
| AstraZeneca | 4 | $86 |
| Dexcom, Inc. | 3 | $72 |
| Amneal Pharmaceuticals LLC | 3 | $67 |
| Novo Nordisk | 3 | $60 |
| Insulet Corporation | 2 | $55 |
| Amgen | 3 | $52 |
| Lundbeck LLC | 3 | $51 |
| GRT US Holding, Inc. | 3 | $50 |
| UCB, Inc. | 2 | $46 |
| Abiomed | 1 | $41 |
| Exact Sciences | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Bayer | 2 | $32 |
| Lilly USA, LLC | 2 | $30 |
| Organogenesis Inc. | 1 | $30 |
| EMD Serono, Inc. | 1 | $30 |
| Ascendis Pharma Endocrinology Inc | 1 | $29 |
| GSK | 2 | $28 |
| Cequr Corporation | 1 | $26 |
| Chiesi USA, Inc. | 1 | $25 |
| Abbott | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Amphastar Pharmaceuticals, Inc. | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $19 |
| Medtronic | 1 | $14 |
| Neurelis, Inc. | 1 | $14 |
How this compares
$2,264 in reported general payments places this provider in the 60th percentile of 229 nephrology providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $14,950 |
| Atorvastatin Calcium | 63 | $720 |
| Amlodipine Besylate | 63 | $458 |
| Rosuvastatin Calcium | 29 | $396 |
| Famotidine | 11 | $360 |
| Losartan Potassium | 23 | $300 |
| Tamsulosin Hcl | 11 | $221 |
| Ezetimibe | 11 | $193 |
| Montelukast Sodium | 11 | $191 |
| Omeprazole | 12 | $180 |
| Fluticasone Propionate | 20 | $142 |
| Metformin Hcl | 13 | $114 |
| Lisinopril | 11 | $65 |
| Hydrochlorothiazide | 14 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $60 | $14,95014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 229 nephrology providers in Tennessee.
Other nephrology in Hermitage
- Claude GalphinChattanooga$2M
- Kendra HendonKnoxville$1.1M
- Wael HusseinMemphis$912K
- Anna BurgnerNashville$788K
- Peter ReeseNashville$613K
- Jamie DwyerNashville$493K
- Ross NesbitKnoxville$452K
- Anthony LangoneNashville$377K
- Rohit GuptaChattanooga$298K
- Adriana HungNashville$270K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.